Ocimum Biosolutions awarded two U.S. patents for gene expression technology

Ocimum Biosolutions has announced issuance of United States Patent No. 7,428,554 which covers the company's proprietary system and method for determining matching patterns within gene expression data and US Patent No. 7426441, which covers methods for determining renal toxins.

The US Patent No. 7,428,554 covers a method for determining matching patterns within gene expression data stored in a database comprising of biological data. This robust methodology helps in retrieving clinically relevant and biologically significant patterns by making optimal use of information imbibed in the biological data which includes biological samples, related information on diseases, medications, tissues and other sample parameters present in the database.

The US Patent No. 7426441 covers the elucidation of global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention also includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

Ms. Anu Acharya, CEO, Ocimum Biosolutions says, "The granting of these patents reflects our continued focus on innovation and commitment to strengthen our intellectual property portfolio. Such cutting-edge research and techniques contribute immensely to our global reputation as a preferred partner for genomic solutions and services with global biotech, pharmaceutical companies and research organizations."